BetaLife Singapore
  • About Us
  • Our Science
  • Our Technology
  • Products and Services
  • Resources
  • Contact

Our Team

Our Facilities

Why BetaLife?

What are iPSCs and Why?

Cell Replacement Therapy

For Institutions

Personalized iPS Cell Banking

Quality Control

FAQs

BROCHURES

MEDIA

Publications

BetaLife Pte Ltd bolsters leadership with appointment of new CSO and Acting CEO

BetaLife Pte Ltd bolsters leadership with appointment of new CSO and Acting CEO

by BetaLife | Mar 3, 2025 | Press Release

BetaLife Pte Ltd has appointed Dr Natasha Hui Jin Ng (吴荟瑾博士) as Chief Scientific Officer (CSO) and acting Chief Executive Officer (CEO) with effect from 3 March 2025. Natasha brings to BetaLife deep scientific expertise and entrepreneurial experience.  She has over 12...
BetaLife and A*STAR Collaborate to Develop Next Generation Cell-based Therapy for Diabetes Treatment

BetaLife and A*STAR Collaborate to Develop Next Generation Cell-based Therapy for Diabetes Treatment

by BetaLife | Mar 22, 2023 | Press Release

BetaLife has acquired the rights to human iPSC technology and cell lines from A*STAR BetaLife and A*STAR sign research collaboration agreement to jointly develop a platform for generating islet cells from human iPSCs with the potential of cell replacement therapy for...

Recent Posts

  • BetaLife Pte Ltd bolsters leadership with appointment of new CSO and Acting CEO
  • BetaLife and A*STAR Collaborate to Develop Next Generation Cell-based Therapy for Diabetes Treatment

Recent Comments

No comments to show.

Locate Us



627A Aljunied Road, #04-02, Biz Tech Centre, Singapore 389842



info@betalife.sg

Follow Us

  • Follow

Privacy Policy    Sitemap

© 2025 by BetaLife Pte Ltd